There is broad interest in developing conformational nanobodies against other complex amyloidogenic proteins, including tau, a large protein (441 amino acids for the longest isoform) associated with Alzheimer’s disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.